Expert Review of Neurotherapeutics · 2016 · 52 citations · 83 references
MedicineNeurologyOncologyAutoimmunityNeuroimmunologyPediatric NeurologyAutoimmune DiseasesAutoimmune Neurological DisordersCentral Nervous System TumorsPediatric Neuro-oncologyPediatric NeuroimmunologyPediatric Neurologic DisordersAutoimmune Paraneoplastic SyndromesOpsoclonus-myoclonus SyndromeParaneoplastic Neurologic SyndromesParaneoplastic Neurological SyndromesPediatric Autoimmune Neurologic DisordersPediatric MyoclonusSmall Cell Lung Cancer AssociationTissue Autoantibodies
Opsoclonus-myoclonus syndrome (OMS) is a rare and primarily immune-mediated disease in children and adults. The main symptoms include opsoclonus, myoclonus and ataxia. In children, the symptoms also include irritability, and, over a long-term course, learning and behavioural disturbances. OMS can be idiopathic, parainfectious or occur as a paraneoplastic (tumour-associated) syndrome. Paraneoplastic OMS in children is almost exclusively associated with neuroblastoma, whereas in adults, small cell lung cancer and breast cancer are the main underlying tumours. An autoimmune pathophysiology is suspected because childhood OMS patients have functionally active autoantibodies, proinflammatory changes in the cytokine network and immunotherapy responses. Children appear to respond regularly to immunosuppressive treatment. However, although the neurological symptoms show a good response, most children continue to show neuropsychological disturbances.
83
Mar Petit‐Pedrol, Thaís Armangué, Xiaoyu Peng et al. · The Lancet Neurology · 2014 · 615 citations · Full text
Medicine, Neurology, Neuroscience +17
Clinical outcome in adult onset idiopathic or paraneoplastic opsoclonus-myoclonus
Luís Bataller · Brain · 2001 · 414 citations · Full text
Medicine, Immunology, Oncology +14
Lithium Carbonate, Haloperidol, and Irreversible Brain Damage
Wendy J. Cohen · JAMA · 1974 · 395 citations
Medicine, Neurology, Pharmacology +14